| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigations |
1 Department of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China
2 Department of Radiology, University of Hong Kong, Hong Kong, China
3 Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital, Hong Kong, China
It is well known that 18F-FDG PET has a high average false-negative rate of 40%–50% in the detection of hepatocellular carcinoma (HCC). This is not an acceptable accuracy, particularly in countries where this tumor is prevalent. In this study, we evaluated prospectively the characteristics of 11C-acetate and 18F-FDG metabolism in HCC and other liver masses. Methods: Fifty-seven patients were recruited into this study, with masses consisting of 39 HCC; 3 cholangiocarcinomas; 10 hepatic metastases from lung, breast, colon, and carcinoid primary malignancies; and 5 benign pathologies, including focal nodular hyperplasia (FNH), adenoma, and hemangioma. All patients, except 2 with typical findings of hemangioma and 3 clinically obvious metastases, were confirmed histopathologically by liver biopsy or resection. All patients fasted for at least 6 h and blood glucose concentration was measured before they underwent dual PET radiopharmaceutical evaluation of the upper abdomen with 11C-acetate and 18F-FDG. Results: In the subgroup of HCC patients with the number of lesions 
3 (32 patients; 55 lesions; mean size ± SD, 3.5 ± 1.9 cm), the sensitivity of detection by 11C-acetate is 87.3% (11C-acetate maximum SUV [SUVmax] = 7.32 ± 2.02, with a lesion-to-normal liver ratio of 1.96 ± 0.63), whereas the sensitivity of detection by 18F-FDG is only 47.3%, and 34% lesions show uptake of both tracers. None of the lesions was negative for both tracers (100% sensitivity using both tracers). In some lesions and in the subgroup of HCC patients (n = 7) with multifocal or diffuse disease, dual-tracer uptake by different parts of the tumor is demonstrated. Histopathologic correlation suggests that the well-differentiated HCC tumors are detected by 11C-acetate and the poorly differentiated types are detected by 18F-FDG. All 16 non-HCC malignant (cholangiocarcinoma and metastatic) liver lesions do not show abnormal 11C-acetate metabolism. Of the benign liver lesions, only FNH shows mildly increased 11C-acetate activities (11C-acetate SUVmax = 3.59, with a lesion-to-normal liver ratio of 1.25). Conclusion: 11C-Acetate has a high sensitivity and specificity as a radiotracer complementary to 18F-FDG in PET imaging of HCC and evaluation of other liver masses.
Key Words: 11C-acetate • PET • hepatocellular carcinoma
This article has been cited by other articles:
|
|
 |
|
  F. Eckel, K. Herrmann, S. Schmidt, C. Hillerer, H. A. Wieder, B.-J. Krause, T. Schuster, R. Langer, H.-J. Wester, R. M. Schmid, et al. Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18F-Fluorothymidine J. Nucl. Med., September 1, 2009; 50(9): 1441 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yun, S.-H. Bang, J. W. Kim, J. Y. Park, K. S. Kim, and J. D. Lee The Importance of Acetyl Coenzyme A Synthetase for 11C-Acetate Uptake and Cell Survival in Hepatocellular Carcinoma J. Nucl. Med., August 1, 2009; 50(8): 1222 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lee, J. C. Paeng, K. W. Kang, H. W. Kwon, K.-S. Suh, J.-K. Chung, M. C. Lee, and D. S. Lee Prediction of Tumor Recurrence by 18F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma J. Nucl. Med., May 1, 2009; 50(5): 682 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sakurai, M. Kaji, and K. Suemasu Thymoma of the Middle Mediastinum: 11C-Acetate Positron Emission Tomography Imaging Ann. Thorac. Surg., April 1, 2009; 87(4): 1271 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Park, J. H. Kim, S. K. Kim, K. W. Kang, K. W. Park, J.-I. Choi, W. J. Lee, C.-M. Kim, and B. H. Nam A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma J. Nucl. Med., December 1, 2008; 49(12): 1912 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamamoto, Y. Nishiyama, R. Kameyama, K. Okano, H. Kashiwagi, A. Deguchi, M. Kaji, and M. Ohkawa Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET J. Nucl. Med., August 1, 2008; 49(8): 1245 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y-x He and Q-y Guo Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms Postgrad. Med. J., May 1, 2008; 84(991): 246 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Zimmerman, R. M. Ghobrial, M. J. Tong, J. R. Hiatt, A. M. Cameron, J. Hong, and R. W. Busuttil Recurrence of Hepatocellular Carcinoma Following Liver Transplantation: A Review of Preoperative and Postoperative Prognostic Indicators Arch Surg, February 1, 2008; 143(2): 182 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-l. Ho, S. Chen, D. W.C. Yeung, and T. K.C. Cheng Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma J. Nucl. Med., June 1, 2007; 48(6): 902 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Ponde, C. S. Dence, N. Oyama, J. Kim, Y.-C. Tai, R. Laforest, B. A. Siegel, and M. J. Welch 18F-Fluoroacetate: A Potential Acetate Analog for Prostate Tumor Imaging--In Vivo Evaluation of 18F-Fluoroacetate Versus 11C-Acetate J. Nucl. Med., March 1, 2007; 48(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaji, H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno 11C-Acetate and 18F-Fluorodeoxyglucose Positron Emission Tomography of Pulmonary Adenocarcinoma Ann. Thorac. Surg., January 1, 2007; 83(1): 312 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohtsuka, H. Nomori, K. Watanabe, T. Naruke, K. Suemasu, N. Kosaka, and K. Uno Positive Imaging of Thymoma by 11C-Acetate Positron Emission Tomography Ann. Thorac. Surg., March 1, 2006; 81(3): 1132 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno 11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lee, W. I. Yang, Y. N. Park, K. S. Kim, J. S. Choi, M. Yun, D. Ko, T.-S. Kim, A. E.H. Cho, H. M. Kim, et al. Different Glucose Uptake and Glycolytic Mechanisms Between Hepatocellular Carcinoma and Intrahepatic Mass-Forming Cholangiocarcinoma with Increased 18F-FDG Uptake J. Nucl. Med., October 1, 2005; 46(10): 1753 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Yau, W.-S. Chan, Y.-M. Tam, P. Vernon, S. Wong, M. Coel, and S. K.-F. Chu Application of Intravenous Contrast in PET/CT: Does It Really Introduce Significant Attenuation Correction Error? J. Nucl. Med., February 1, 2005; 46(2): 283 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Scholmerich and D Schacherer Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut, September 1, 2004; 53(9): 1224 - 1226. [Full Text] [PDF]
|
|
|
|
|
|
D. Delbeke and C. W. Pinson 11C-Acetate: A New Tracer for the Evaluation of Hepatocellular Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 222 - 223. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
